The Management of Linezolid-Induced Adverse Events in Shorter and Longer Treatment of Rifampicin-Resistant Tuberculosis.

Background: Linezolid is included in most of the regimens for treatment of rifampicin-resistant tuberculosis. The prior publications presented the safety profile and clinical effectiveness of linezolid.

Objectives: The research objectives of this study include: description of cumulative incidence rates of linezolid-induced adverse events, assessment of associations of those events with different variables, evaluation of the adverse event management and impacts of the unfavorable events on the effectiveness of treatment for rifampicin-resistant tuberculosis.

Vitamin D Supplementation and Remission from Chronic Anterior Uveitis.

Purpose: Chronic anterior uveitis (CAU) often requires suppressive therapy, which has potential side effects including cataract, ocular hypertension, and increased risk of infection. No remittive therapy is currently available; however, several studies have demonstrated an association between low 25-hydroxy Vitamin D (25OHD) levels and either uveitis incidence or uveitis disease activity. This study investigates the potential of Vitamin D supplementation as a remittive treatment for CAU.

Grandiose narcissism, unfounded beliefs, and behavioral reactions during the COVID-19 pandemic.

A theoretical perspective on grandiose narcissism suggests four forms of it (sanctity, admiration, heroism, rivalry) and states that these forms conduce to different ways of thinking and acting. Guided by this perspective, we examined in a multinational and multicultural study (61 countries; N = 15,039) how narcissism forms are linked to cognitions and behaviors prompted by the COVID-19 pandemic. As expected, differences in cognitions and behaviors across narcissism forms emerged.

Operational research as a mechanism to improve treatment outcomes for drug-resistant TB in the WHO European Region.

In 2022, the WHO European Region accounted for 15.1% of all incident rifampicin-resistant/multidrug-resistant TB (RR/MDR-TB) cases. Most occurred in 18 high-priority countries of eastern Europe and central Asia, many of which joined an initiative led by the WHO Regional Office for Europe.